Are investors shorting Immuron?

Immuron saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 25,700 shares, a decrease of 49.8% from the March 15th total of 51,200 shares. Based on an average daily trading volume, of 872,600 shares, the short-interest ratio is presently 0.0 days. View Immuron's Short Interest .

What other stocks do shareholders of Immuron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immuron investors own include Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Gilead Sciences (GILD) , Inovio Pharmaceuticals (INO) , Pfizer (PFE) , CRISPR Therapeutics (CRSP) , Dynavax Technologies (DVAX) , OPKO Health (OPK) , AbbVie (ABBV) and Co-Diagnostics (CODX) .

When did Immuron IPO?

Immuron (IMRN) raised $6 million in an IPO on Friday, June 9th 2017. The company issued 600,000 shares at a price of $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager.

NASDAQ:IMRN

Immuron (IMRN) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free IMRN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $2.57
▼
$2.74
50-Day Range: $4.80
▼
$5.61
52-Week Range: $1.92
▼
$28.99

Volume: 8,199 shs
Average Volume: 27,923 shs
Market Capitalization: $14.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Headlines Ownership Short Interest Social Media

Get Immuron alerts:

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Immuron Stock (NASDAQ:IMRN)

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

IMRN Stock News Headlines

April 15, 2024 | finance.yahoo.com

Immuron Limited (IMRN) Interactive Stock Chart - Yahoo Finance

April 15, 2024 | globenewswire.com

Immuron to host Live Virtual Event

April 16, 2024 | Crypto Swap Profits (Ad)

Claim Your Complimentary Bitcoin Reward

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

April 10, 2024 | finanznachrichten.de

Immuron Limited: Immuron Travelan sales continued strong growth

April 10, 2024 | msn.com

Immuron gains after Travelan sales update

April 10, 2024 | globenewswire.com

Immuron Travelan® sales continued strong growth

March 27, 2024 | ca.finance.yahoo.com

Immuron Limited (IMRN) Latest Stock News & Headlines - Yahoo Finance

March 22, 2024 | investing.com

Immuron Ltd ADR (IMRN)

April 16, 2024 | Crypto Swap Profits (Ad)

Claim Your Complimentary Bitcoin Reward

March 7, 2024 | msn.com

Immuron surges after mid-stage data for antidiarrheal med

March 7, 2024 | globenewswire.com

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

March 7, 2024 | msn.com

ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3

February 22, 2024 | benzinga.com

Immuron Stock (NASDAQ:IMRN) Dividends: History, Yield and Dates

February 21, 2024 | globenewswire.com

Immuron Presentation Australian Biologics Festival 2024

February 13, 2024 | finanznachrichten.de

Immuron Limited: Immuron achieves record Travelan sales

February 13, 2024 | finance.yahoo.com

Immuron achieves record Travelan® sales

January 16, 2024 | finanznachrichten.de

Immuron Limited: Immuron achieves record half yearly Travelan sales

January 16, 2024 | finance.yahoo.com

Immuron achieves record half yearly Travelan® sales

January 15, 2024 | msn.com

ASX Health Stocks: Immuron chalks up record half for travelers’ diarrhoea medicine, Travelan

January 15, 2024 | au.investing.com

Immuron chalks up stellar half-year Travelan sales as travel returns to pre-pandemic levels

December 22, 2023 | finance.yahoo.com

Immuron Clinical Trials Update

December 4, 2023 | proactiveinvestors.com

Immuron enrols first patients in Campylobacter Challenge clinical study

December 4, 2023 | markets.businessinsider.com

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

November 28, 2023 | finance.yahoo.com

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

November 13, 2023 | finance.yahoo.com

Immuron CEO Steven Lydeamore Investor Webinar Presentation

November 1, 2023 | au.investing.com

Immuron receives bull case valuation of A$0.35 from Pitt Street Research

October 31, 2023 | proactiveinvestors.com

Immuron receives bull case valuation of A$0.35 from Pitt Street...

See More Headlines

Receive IMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuron and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/16/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IMRN
CUSIP: N/A
CIK: 1660046
Web: www.immuron.com.au
Phone: (138) 892-4854
Fax: 6103 98227735
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.52
Quick Ratio: 7.79

Sales & Book Value

Annual Sales: $1.22 million
Price / Sales: 12.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.32 per share
Price / Book: 1.12

Miscellaneous

Outstanding Shares: 5,700,000
Free Float: 5,300,000
Market Cap: $14.76 million
Optionable: Not Optionable
Beta: 1.43

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Jerry Kanellos Ph.D. (Age 60)
CEO & COO
Comp: $189.27k
Mr. Peter Anastasiou (Age 61)
Exec. Vice Chairman
Comp: $29.02k
Mr. Phillip Allen Hains (Age 62)
CFO & Company Sec.
Mr. David Lyon
Head of Marketing
Dr. Dan Ruben Peres (Age 45)
Chief Medical Officer

Key Competitors

View All Competitors

IMRN Stock Analysis - Frequently Asked Questions

Are investors shorting Immuron?: Immuron saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 25,700 shares, a decrease of 49.8% from the March 15th total of 51,200 shares. Based on an average daily trading volume, of 872,600 shares, the short-interest ratio is presently 0.0 days.
View Immuron's Short Interest.
What other stocks do shareholders of Immuron own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Immuron investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), CRISPR Therapeutics (CRSP), Dynavax Technologies (DVAX), OPKO Health (OPK), AbbVie (ABBV) and Co-Diagnostics (CODX).
When did Immuron IPO?: Immuron (IMRN) raised $6 million in an IPO on Friday, June 9th 2017. The company issued 600,000 shares at a price of $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager.

This page (NASDAQ:IMRN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immuron (IMRN) Stock Price, News & Analysis

About Immuron Stock (NASDAQ:IMRN)

IMRN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

IMRN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info